Global Markets Direct Market Research Reports

TITLE	Actions
Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...
Q Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Q Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Q Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Q Fever pipe...
Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or CDK11 or CDK19 or EC 2.7.11.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or CDK11 or CDK19 or EC 2.7.11.22) Drugs in Developme...
Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ...
Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and ...
C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players ...
Ketohexokinase (Hepatic Fructokinase or KHK or EC 2.7.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Ketohexokinase (Hepatic Fructokinase or KHK or EC 2.7.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary Ketohexokinase (Hepatic Fructokinase or KHK or EC 2.7....
Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an ...
Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an over...
Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...
Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...
Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, ...
Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary Cytosolic Phosphol...
Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TACSTD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TACSTD2) Drugs in Development by Therapy Areas and I...
DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and I...
C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary C-C Chemokine Receptor...
Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5)...
Prurigo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Prurigo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Prurigo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Prurigo pipe...
Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...
Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA,...

We are on:

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *

TITLE	Actions
Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...
Q Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Q Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Q Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Q Fever pipe...
Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or CDK11 or CDK19 or EC 2.7.11.22) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cyclin Dependent Kinase 19 (CDC2 Related Protein Kinase 6 or Cell Division Cycle 2 Like Protein Kinase 6 or Cell Division Protein Kinase 19 or Cyclin Dependent Kinase 11 or Death Preventing Kinase or CDK11 or CDK19 or EC 2.7.11.22) Drugs in Developme...
Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ADRB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary Beta 3 Adrenergic Receptor (Beta 3 Adrenoreceptor or ...
Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and ...
C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct C-C Chemokine Receptor Type 8 (CC Chemokine Receptor CHEMR1 or CMKBRL2 or Chemokine Receptor Like 1 or GPR CY6 or TER1 or CDw198 or CCR8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players ...
Ketohexokinase (Hepatic Fructokinase or KHK or EC 2.7.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Ketohexokinase (Hepatic Fructokinase or KHK or EC 2.7.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary Ketohexokinase (Hepatic Fructokinase or KHK or EC 2.7....
Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Spinal Cord Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an ...
Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an over...
Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...
Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...
Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, ...
Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary Cytosolic Phosphol...
Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TACSTD2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Cells Expressing Tumor Associated Calcium Signal Transducer 2 (Cell Surface Glycoprotein Trop 2 or Membrane Component Chromosome 1 Surface Marker 1 or Pancreatic Carcinoma Marker Protein GA733-1 or TACSTD2) Drugs in Development by Therapy Areas and I...
DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary DNA Topoisomerase II (EC 5.99.1.3) Drugs in Development by Therapy Areas and I...
C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Summary C-C Chemokine Receptor...
Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5)...
Prurigo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Prurigo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Prurigo Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Prurigo pipe...
Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2000 Onwards \| By Global Markets Direct Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players Summary Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...
Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players Published in May 2022 \| US $ 2500 Onwards \| By Global Markets Direct Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA,...